<DOC>
	<DOCNO>NCT01497548</DOCNO>
	<brief_summary>Primary Objective To determine efficacy Methylphenidate add therapy mirtazapine treatment depression cancer patient palliative care Hypothesis Methyphenidate add mirtazapine treat subject show significant early reduction ( Montgomery Asberg Depression Rating Scale ) MADRS baseline Day 3 . Secondary Objective 1 . To determine efficacy Methylphenidate add therapy mirtazapine treatment anxiety cancer patient palliative care . Hypothesis Methyphenidate add mirtazapine treat subject show significant early reduction anxiety score HADS Mirtazepine alone treat subject baseline Day 3 . 2 . To determine efficacy Methylphenidate add therapy mirtazapine reduce distress cancer patient palliative care . Hypothesis Methyphenidate add mirtazapine treat subject show significant early reduction distress score distress thermometer Mirtazepine alone treat subject baseline Day 3 . 3 . To determine efficacy Methylphenidate add therapy mirtazapine improve function cancer patient palliative care . Hypothesis Methyphenidate add mirtazapine treat subject show increase ( Eastern Cooperation Group performance status ) ECOG score Mirtazepine alone treat subject baseline Day 3 4 . To determine efficacy Methylphenidate add therapy mirtazapine reduce somatic complaint cancer patient palliative care . Hypothesis Methyphenidate add mirtazapine treat subject show significant early reduction score Numeric Rating Scale ( NRS ) Pain Visual Analogue Scale ( VAS ) Fatigue Mirtazapine alone treat subject baseline Day 3 .</brief_summary>
	<brief_title>Study Methylphenidate Add Therapy Depressed Cancer Patients</brief_title>
	<detailed_description>Background Cancer remain one fear illnesses diagnosis cancer huge psychological impact patient care-takers ( Knobf , 2007 ) . Depression one common psychiatric sequella ( Derogatis et al. , 1983 ) 2 affect quality life , compliance treatment , disease advancement , tolerability pain fatigue cancer patient ( Bennett et al. , 2004 ; Sommerset , 2004 ; Green et al. , 2009 ) . However , likely depression under-recognized under-treated cancer patient ( Kadan-Lottick et al. , 2005 ) . Depressed feeling manifest spectrum range normal sadness variety mood disturbance clinical presentation . It challenge differentiate clinical depression `` normal '' emotional distress cancer patient somatic symptom fatigue , loss appetite weight , sleep difficulty , poor memory concentration may mirror physiological symptom cause cancer treatment ( McDaniel Musselman , 1995 ; Masie Popkin , 1998 ; Cochinov , 2001 ; Jesse et al. , 2008 ) . This complicate diagnosis depression cancer patient ( McDaniel Musselman , 1995 ; Masie Popkin , 1998 ; Cochinov , 2001 ; Pasquini Biond , 2007 ; Jesse et al. , 2008 ) . Many study investigate prevalence depression cancer past decade . A previous review Mc Daniel et al , report prevalence major depression range 4.8 % 9.2 % base study use standardized diagnostic interview cancer outpatient . Prevalence rate higher admitted cancer patient ( 8 % Major Depression 15 % 36 % depressive disorder ) ( McDaniel Musselman , 1995 ) . A preliminary systematic review prevalence depression cancer patient conduct investigator study . It show major depressive disorder high 10.8 % cancer patient base structured clinical interview . In addition high prevalence , uncertainty exists respect optimal treatment depression cancer . Although huge number study investigate efficacy pharmacotherapy depression general population , number randomize , control trial antidepressant depression cancer patient conduct limited ( Challman Lipsky , 2000 ; Raison Miller , 2003 ) . A comprehensive systematic review look effectiveness tolerability antidepressant treatment depress cancer patient perform publish Rodin et al 2007 . Although 7 trial identify , author comment number positive randomize trial limit need rigorous study newer agent alternative treatment option ( Raison Miller , 2003 ) . The preliminary systematic review conduct investigator study also come conclusion . Psychostimulants methylphenidate propose treatment depressed patient rapid onset action ( Masand Tesar , 1995 ; Challman Lipsky , 2000 ; Rozans et al. , 2002 ; Kaminski Sjogren , 2007 ) . They may antidepressant effect may advantageous due rapid onset action ( Candy et al. , 2008 ) . Some study suggest provide safe effective treatment depression cancer patient ( Masand Tesar , 1995 ) alleviate opioid induced somnolence , improve cognitive function ameliorate pain cancer patient . Another potential advantage use psychostimulant cancer patient ability improve multiple somatic symptom irrespective etiology ( Vigano et al. , 1995 ) . However , number study look efficacy psychostimulant improve depressive mood cancer limit . Five study identify review conduct investigator study . Although show positive result use methylphenidate depress cancer patient , open-label without control group . There one double blind , randomise placebo control study use methylphenidate cancer patient publish French language ( Laval , 2008 ) .Considering lack randomize control trial topic , need study efficacy tolerability psychostimulant methylphenidate add therapy depression cancer patient inevitably need . Primary Objective To determine efficacy Methylphenidate add therapy mirtazapine treatment depression cancer patient Secondary Objective 1 . To determine efficacy Methylphenidate add therapy mirtazapine treatment anxiety cancer patient . 2 . To determine efficacy Methylphenidate add therapy mirtazapine reduce distress cancer patient . 3 . To determine efficacy Methylphenidate add therapy mirtazapine improve function cancer patient . 4 . To determine efficacy Methylphenidate add therapy mirtazapine reduce somatic complaint cancer patient . Study Design Design An open label , parallel group , placebo control study methylphenidate add therapy mirtazapine . Procedure Subjects male female current diagnosis cancer type DSM-IV diagnosis major depressive disorder . They identify oncology , surgical palliative clinic ward . Depressive symptom measure screen MADRS . Sixty ( 120 ) subject recruit start mirtazapine 30mg night . They randomize one two group ( 60 subject per group ) : Methylphenidate Placebo add therapy . All treatment initiate screen continue 28 day outpatient inpatient treatment . Efficacy evaluation take place baseline , day 3 , day 6 , 9 , 14 , 21 day 28 . At end 28 day , continuation treatment depend investigator 's clinical judgment End Medication Evaluation perform . Every effort make continue evaluate subject randomize even decide discontinue medication . Project Timetable The project take 2 year . The plan randomize 2 subject per week , take 15 month acquire 120 subject . All subject complete study drug treatment 18 month elapse . Follow-up evaluation complete 2 year start project . Primary Study Endpoints The primary endpoint measure study : - MADRS baseline , Day 3 , 6 , 9 , 14 , 21 28 . Secondary Study Endpoints The secondary endpoint measure : - Anxiety HADS baseline , Day 3 , 6 , 9 , 14 , 21 28 - Distress score distress thermometer baseline , Day 3 , 6 , 9 , 14 , 21 28 - Karnofsky Scale baseline , Day 3 , 6 , 9 , 14 , 21 28 - Numeric Rating Scale ( NRS ) Pain baseline , Day 3 , 6 , 9 , 14 , 21 28 - Visual Analogue Scale ( VAS ) Fatigue baseline , Day 3 , 6 , 9 , 14 , 21 28 Primary Safety Endpoints The primary safety endpoint measurement collection serious adverse event occur initial study treatment include 14 day cessation study treatment .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Male female , age &gt; 18 year . 2 . Current DSM IV diagnosis Major Depressive Disorder . 3 . Under palliative care . 4 . Confirmed diagnosis cancer . 5 . Not antidepressants 1 . Clinical significant abnormal laboratory value . 2 . Clinically significant abnormal ECG . 3 . Documented history psychiatric diagnosis ( schizophrenia , bipolar disorder , organic brain disorder , dementia etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Depression</keyword>
	<keyword>cancer</keyword>
	<keyword>methylphenidate</keyword>
	<keyword>pharmacotherapy</keyword>
</DOC>